Glioblastoma (GBM) is characterized by exceptionally high intratumoral heterogeneity. However, the molecular mechanisms underlying the origin of different GBM cell populations remain unclear. Here, we found that the compositions of ribosomes of GBM cells in the tumour core and edge differ due to alternative RNA splicing. The acidic pH in the core switches before messenger RNA splicing of the ribosomal gene RPL22L1 towards the RPL22L1b isoform. This allows cells to survive acidosis, increases stemness and correlates with worse patient outcome. Mechanistically, RPL22L1b promotes RNA splicing by interacting with lncMALAT1 in the nucleus and inducing its degradation. Contrarily, in the tumour edge region, RPL22L1a interacts with ribosomes in th...
Abstract Aggressiveness and drug resistance are major challenges in the clinical treatment of gliobl...
Within the glioblastoma cellular niche, glioma stem cells (GSCs) can give rise to differentiated gli...
Tumour cell plasticity is a major barrier to the efficacy of targeted cancer therapies but the mecha...
Glioblastoma (GBM) is characterized by exceptionally high intratumoral heterogeneity. However, the m...
Glioblastomas remain the deadliest brain tumour, with a dismal ∼12-16-month survival from diagnosis....
Glioblastomas remain the deadliest brain tumour, with a dismal ∼12-16-month survival from diagnosis....
Although glioblastoma (GBM) stem-like cells (GSCs), which retain chemo-radio resistance and recurren...
Background: Glioblastoma, the most aggressive primary brain tumor, is genetically heterogeneous. Alt...
Aggressive cancers such as glioblastoma (GBM) contain intermingled apoptotic cells adjacent to proli...
BackgroundAlternative splicing is a rich source of tumor-specific neoantigen targets for immunothera...
Alternative RNA splicing plays an integral role in cell fate determination and function, especially ...
Alternative RNA splicing plays an integral role in cell fate determination and function, especially ...
Glioblastoma (GBM) is a devastating malignancy with few therapeutic options. We identify PRMT5 in an...
Therapy resistance and recurrence in high-grade gliomas are driven by their populations of glioma st...
The concept of cancer stem-like cells (CSCs) has gained considerable attention in various solid tumo...
Abstract Aggressiveness and drug resistance are major challenges in the clinical treatment of gliobl...
Within the glioblastoma cellular niche, glioma stem cells (GSCs) can give rise to differentiated gli...
Tumour cell plasticity is a major barrier to the efficacy of targeted cancer therapies but the mecha...
Glioblastoma (GBM) is characterized by exceptionally high intratumoral heterogeneity. However, the m...
Glioblastomas remain the deadliest brain tumour, with a dismal ∼12-16-month survival from diagnosis....
Glioblastomas remain the deadliest brain tumour, with a dismal ∼12-16-month survival from diagnosis....
Although glioblastoma (GBM) stem-like cells (GSCs), which retain chemo-radio resistance and recurren...
Background: Glioblastoma, the most aggressive primary brain tumor, is genetically heterogeneous. Alt...
Aggressive cancers such as glioblastoma (GBM) contain intermingled apoptotic cells adjacent to proli...
BackgroundAlternative splicing is a rich source of tumor-specific neoantigen targets for immunothera...
Alternative RNA splicing plays an integral role in cell fate determination and function, especially ...
Alternative RNA splicing plays an integral role in cell fate determination and function, especially ...
Glioblastoma (GBM) is a devastating malignancy with few therapeutic options. We identify PRMT5 in an...
Therapy resistance and recurrence in high-grade gliomas are driven by their populations of glioma st...
The concept of cancer stem-like cells (CSCs) has gained considerable attention in various solid tumo...
Abstract Aggressiveness and drug resistance are major challenges in the clinical treatment of gliobl...
Within the glioblastoma cellular niche, glioma stem cells (GSCs) can give rise to differentiated gli...
Tumour cell plasticity is a major barrier to the efficacy of targeted cancer therapies but the mecha...